Febuxostat vs allopurinol: real-world cardiovascular safety

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1762卷 / 1期
关键词：
D O I：
10.1007/s40278-019-64745-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [21] UPDATE ON COMPARATIVE CARDIOVASCULAR SAFETY OF FEBUXOSTAT VERSUS ALLOPURINOL AMONG PATIENTS WITH GOUT
    Shin, A.
    Ha, Y. J.
    Lee, Y. J.
    Lee, E. B.
    Kang, E. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 385 - 385
  • [22] Cardiovascular Risk in Gout Patients Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)
    Mueller-Wieland, D.
    Nitschmann, S.
    INTERNIST, 2018, 59 (11): : 1224 - 1228
  • [23] Higher risk of deaths with febuxostat vs allopurinol
    Reactions Weekly, 2017, 1680 (1) : 2 - 2
  • [24] No increased cardiovascular risk with febuxostat versus allopurinol
    Reactions Weekly, 2020, 1830 (1) : 10 - 10
  • [25] FEBUXOSTAT, ALLOPURINOL AND CARDIOVASCULAR RISK: MYTH OR REALITY?
    MacDonald, Thomas
    RHEUMATOLOGY, 2019, 58
  • [26] Cardiovascular safety of insulin: Between real-world data and reality
    Mannucci, Edoardo
    Ferrannini, Ele
    DIABETES OBESITY & METABOLISM, 2017, 19 (09): : 1201 - 1204
  • [27] Cardiovascular Safety of Febuxostat
    Bhattacharyya, Shamik
    Macklin, Eric A.
    Schwarzschild, Michael A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (16): : 1582 - 1582
  • [28] Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
    Patoulias, Dimitrios Ioannis
    Doumas, Michael
    REUMATOLOGIA, 2021, 59 (06): : 423 - 424
  • [29] Diabetes and gout: efficacy and safety of febuxostat and allopurinol
    Becker, M. A.
    MacDonald, P. A.
    Hunt, B. J.
    Jackson, R. L.
    DIABETES OBESITY & METABOLISM, 2013, 15 (11): : 1049 - 1055
  • [30] Cardiovascular safety of febuxostat
    Singh, Jasvinder A.
    LANCET, 2021, 398 (10304): : 955 - 955
12345